CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ANG Lifesciences India Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ANG Lifesciences India Ltd
SCO 113, 1st Floor, Darbara Complex
Ranjit Avenue, B-Block
Phone: +91 1835070118p:+91 1835070118 AMRITSAR, 143001  India Ticker: 540694540694
Business Summary
ANG Lifesciences India Limited is an India-based pharmaceutical company. The Company is engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials. It operates in two segments, namely pharmaceuticals and printing and packaging. The Company's product portfolio includes various products comprising therapeutic categories, such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin and Beta Lactamase Inhibitor. The Company’s product category includes Dry Powder Injection, Liquid Injections, Hard Gelatin Capsule, Tablet Beta Lactum, Tablets, Liquid Suspension /Syrup, Ointment/Creams, and Soft Gelatin Capsule. Its Dry Powder Injection products include Ampicillin & Cloxacillin for injection 500mg, Azetronam for Injection USP 500mg, Ampicillin Injection 1.0gm, Ceftriaxone Injection 250mg, Amoxycillin & Potassium Clavulanate for injection 1.2gm, and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Managing Director, Director RajeshGupta 46 10/1/2016 10/1/2016
Additional Non-Executive Non-Independent Director RohitMittal 10/10/2023 10/10/2023
Additional Non-Executive Independent Director Chetna.. 33 10/12/2021 10/12/2021
Non-Executive Independent Director SukhpalSingh 43 5/2/2016 5/2/2016

Business Names
Business Name
540694
Mansa Print & Publishers Ltd.

General Information
Number of Employees: 433 (As of 3/31/2024)
Outstanding Shares: 13,058,287 (As of 9/30/2024)
Shareholders: 7,035
Stock Exchange: BOM


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, January 27, 2025